Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (RNA)-modulating, therapeutics for the treatment of genetic disorders. The Company's primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. The Company's clinical portfolio of RNA-based product candidates is focused on the treatment of Duchenne muscular dystrophy (DMD). The Company's platform technology allows the development of RNA-modulating therapeutics that either interferes with splicing (exon skipping, exon inclusion, or splice mutation correction), remove mutant RNA, or block RNA expression, for different indications.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NYSE:RNA
- CUSIP: N/A
- Web: www.prosensa.eu
- 50 Day Moving Avg: $19.00
- 200 Day Moving Avg: $17.00
- 52 Week Range: $4.00 - $23.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.00
- P/E Growth: 0
- Return on Equity: -72.90%
- Return on Assets: -57.94%
- Average Volume: 187,002 shs.
Frequently Asked Questions for Prosensa Holding NV (NYSE:RNA)
What is Prosensa Holding NV's stock symbol?
Prosensa Holding NV trades on the New York Stock Exchange (NYSE) under the ticker symbol "RNA."
How were Prosensa Holding NV's earnings last quarter?
Prosensa Holding NV (NYSE:RNA) released its earnings results on Monday, November, 17th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.04. View Prosensa Holding NV's Earnings History.
Who are some of Prosensa Holding NV's key competitors?
Some companies that are related to Prosensa Holding NV include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Seattle Genetics (SGEN), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), United Therapeutics Corporation (UTHR), Icon Plc (ICLR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), Galapagos NV (GLPG), Portola Pharmaceuticals (PTLA), ACADIA Pharmaceuticals (ACAD) and Puma Biotechnology (PBYI).
How do I buy Prosensa Holding NV stock?
Shares of Prosensa Holding NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prosensa Holding NV's stock price today?
MarketBeat Community Rating for Prosensa Holding NV (NYSE RNA)MarketBeat's community ratings are surveys of what our community members think about Prosensa Holding NV and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Prosensa Holding NV stock can currently be purchased for approximately $19.00.
Consensus Ratings for Prosensa Holding NV (NYSE:RNA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Prosensa Holding NV (NYSE:RNA)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Prosensa Holding NV (NYSE:RNA)Earnings History by Quarter for Prosensa Holding NV (NYSE RNA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/20/2014||Q114||$0.01||$0.26||$18.38 million||$20.23 million||View||N/A|
|3/17/2014||($0.14)||($0.12)||$2.92 million||$3.03 million||View||N/A|
Earnings Estimates for Prosensa Holding NV (NYSE:RNA)
Current Year EPS Consensus Estimate: $-1 EPS
Next Year EPS Consensus Estimate: $-1 EPS
Dividend History for Prosensa Holding NV (NYSE:RNA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Prosensa Holding NV (NYSE:RNA)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Prosensa Holding NV (NYSE:RNA)
Latest Headlines for Prosensa Holding NV (NYSE:RNA)
Prosensa Holding NV (RNA) Chart for Saturday, July, 22, 2017